Compounds 1–6 and 9 were evaluated for their inhibitory activity against type 4 phosphodiesterase (PDE4), which is a fascinating drug target for treatment of inflammatory, respiratory, and neurological diseases. This evidence concerns the gene PDE4A and nervous system disorder.